COMMUNIQUÉS West-GlobeNewswire

Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Ryan Maynard as Chief Financial Officer
23/02/2026
WATERTOWN, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting [...]
Novo Nordisk A/S: CagriSema demonstrated 23% weight loss in an open-label head-to-head REDEFINE 4 trial in people with obesity, the primary endpoint was not achieved
23/02/2026
CagriSema achieved 23% weight loss after 84 weeks of treatment CagriSema 2.4/2.4 mg did not meet the primary endpoint of showing non-inferiority on weight loss compared to tirzepatide 15 mg at 84 weeks 1 Additional [...]
Anteris to Present at Healthcare Investor Conferences TD Cowen and Barclays
23/02/2026
MINNEAPOLIS and BRISBANE, Australia, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR) a global structural heart company committed to designing, [...]
Apellis Pharmaceuticals to Present at the TD Cowen 46th Annual Health Care Conference
23/02/2026
WALTHAM, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will participate in a webcast fireside chat at the TD Cowen 46th Annual Health Care [...]
TOMI Environmental Solutions Receives Biocidal Product Approvals in Great Britain and Northern Ireland
23/02/2026
Health and Safety Executive (HSE) grants Authorization Nos.: GB-2016-1042 and NI-2026-1350 FREDERICK, Md., Feb. 23, 2026 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global leader [...]
Novartis presents Rhapsido® (remibrutinib) data at AAAAI, showing potential beyond chronic spontaneous urticaria (CSU)
23/02/2026
Analyses from REMIX-1 & -2 studies on CSU disease control and early symptom relief will be presented Phase II data evaluating safety and efficacy results of remibrutinib for treatment of peanut allergy to be [...]
Pulselight platform now available to NHS via £10bn Fortrus Framework
23/02/2026
Pulselight’s platform can now be procured for NHS organisations via this pre-approved route to market LONDON, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Pulselight, a leading healthcare data analytics provider, is now an [...]
RE+Vitalize Health and Nutrition Announces Initiative to Advance Clean and Transparent Supplement Standards
23/02/2026
Elizabeth City, NC, Feb. 23, 2026 (GLOBE NEWSWIRE) -- RE+Vitalize Health and Nutrition, a retail health and nutrition brand based in Elizabeth City, announced an initiative focused on advancing clean and transparent [...]
argenx to Present at TD Cowen 46th Annual Healthcare Conference
23/02/2026
February 23, 2026 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that [...]
Opterion Health AG Announces First Patient enrolled in Phase 1 SPARC Trial Following CTA Approval for OPT101
23/02/2026
MUTTENZ, Switzerland, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Opterion Health AG today announced that the first patient has been successfully enrolled in its Phase 1 SPARC trial. This marks the official start of the company’s [...]
Dyne Therapeutics Announces Upcoming Presentations Across Neuromuscular Pipeline at 2026 MDA Clinical & Scientific Conference
22/02/2026
- Late-breaking poster to feature new positive cardiopulmonary function results from the DELIVER trial of z-rostudirsen in DMD - - Oral presentation on Phase 3 trial design for z-basivarsen in DM1 - - Five total [...]
Gyder Surgical announces first commercial surgical cases in the United States performed by Dr. Paul M. Lombardi, M.D., at the Tri-County Orthopedics’ Joint Replacement Institute outpatient center
22/02/2026
The GYDER® Navigation System is the world’s first commercially available pin-less & image-less computer assisted technology for real time guidance during Total Hip Arthroplasty using the Anterior Approach PALO ALTO [...]
Sixth Annual Neuroscience and Yoga Conference Announced by NeuroYogaNYC
22/02/2026
A Global Online Event to Explore Yoga's Impact on Migraine, Child Development, Neurodiversity, Brain Longevity and Healthy Brain Aging, and more New York, NY, Feb. 22, 2026 (GLOBE NEWSWIRE) -- NeuroYogaNYC , a leader in [...]
MoonLake Announces Positive Topline Results from its Phase 2 Clinical Trial of Sonelokimab in Axial Spondyloarthritis and Reports 2025 Financial Results
22/02/2026
In the Phase 2 S-OLARIS clinical trial in axial spondyloarthritis (axSpA), sonelokimab (SLK) demonstrated clinically meaningful benefit with 80+% of patients achieving ASAS40 by Week 12 Consistently, other clinical and [...]
Thermobalancing therapy emerges as drug-free option for BPH, chronic prostatitis, back pain and kidney stones
21/02/2026
The advantages of Thermobalancing therapy with Dr Allen's Devices, a new revolutionary medical technology for benign prostatic hyperplasia (BPH), kidney stones and other health conditions, have been widely discussed at [...]
Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical Efficacy and Safety Analyses in Inflammatory Bowel Disease at ECCO 2026
21/02/2026
Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical Efficacy and Safety Analyses in Inflammatory Bowel Disease at ECCO 2026 22 abstracts presented at European Crohn’s and [...]
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
20/02/2026
SAN DIEGO, Feb. 20, 2026 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or “the Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from [...]
Amicus Therapeutics Announces Full-Year 2025 Financial Results and Corporate Updates
20/02/2026
2025 Total Revenue of $634M, up 17% Year-over-Year at CER Cash Position of $294M, a $44M Increase in 2025 Proposed Acquisition by BioMarin Expected to Close in Q2 2026, Subject to Closing Conditions PRINCETON, N.J., Feb [...]
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
20/02/2026
MALVERN, Pa., Feb. 20, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today [...]

Pages